ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by ProPhase Labs, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for ProPhase Labs, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Karkus Ted William | CEO & CHAIRMAN | 150,000Indirect | Sep 11, 2025 | 0 |
| Hollenshead Stuart | Chief Operating Officer | – | Feb 21, 2025 | 0 |
| Gleckel Louis MD | Director | – | Feb 18, 2025 | 0 |
| Hirsch Warren | Director | – | Feb 18, 2025 | 0 |
| Latkin Jed | Director | – | Mar 19, 2024 | 0 |
| Barr Jason Michael | Director | 30,962 | Mar 19, 2024 | 0 |
| Morse Robert A. Jr. | CHIEF FINANCIAL OFFICER | – | Apr 6, 2023 | 0 |
| Brady Monica L. | Chief Accounting Officer | 34,872 | May 25, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 11, 2022 (view filing) | Mar 10 | 32 days | Barr Jason MichaelDirector | PPurchaseCommon Stock, par value $0.0005 | +721 | $6.48 | +$4.67K | +2.4%31.0K after | Amended |